Ayudhya R K, Yipintsoi T, Jintapakorn W, Suntiparpluacha C, Yipintsoi S
Department of Medicine, Faculty of Medicine, Prince of Songkla University, Hat Yai, Thailand.
J Med Assoc Thai. 1990 Mar;73(3):162-7.
The effect of trimetazidine was evaluated in patients with stable angina by adding it to the other antianginal regimen in a double blind crossover design each of 8 week's duration. The method of evaluation made use of symptom recall, daily dairy of the intake of sublingual nitrates or of anginal discomfort and in some, symptom limited treadmill exercise stress test (EST). Thirty-six patients completed the trial. Symptom-wise, 16 patients could not differentiate the effect of the true tablet from the placebo. Eight had less and 12 had more angina while on the drug. Of the 17 evaluable EST, 9 showed no change in the degree of ischemic changes while 4 performed with less and 4 with more ischemia while on the drug. Symptom-wise and taking into account the pre and post trial periods, a placebo effect was not found to be dominant. It is concluded that trimetazidine does not improve angina among those already being treated with conventional doses of nitrates, beta and calcium blockers.
采用双盲交叉设计，每次持续8周，在稳定型心绞痛患者中，将曲美他嗪添加到其他抗心绞痛治疗方案中，评估其疗效。评估方法包括症状回忆、舌下硝酸酯类药物摄入或心绞痛不适的日常记录，部分患者还进行了症状限制性平板运动应激试验（EST）。36名患者完成了试验。从症状方面来看，16名患者无法区分真正药物片剂和安慰剂的效果。8名患者用药期间心绞痛减轻，12名患者用药期间心绞痛加重。在17例可评估的EST中，9例缺血变化程度无改变，4例用药期间缺血减轻，4例用药期间缺血加重。从症状方面并考虑试验前后情况，未发现安慰剂效应占主导。得出的结论是，在已经接受常规剂量硝酸盐、β受体阻滞剂和钙通道阻滞剂治疗的患者中，曲美他嗪不能改善心绞痛。
